Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma

David Propper, John Bridgewater, Limas Kupčinskas, A. Fittipaldo, Carina Hillenbach, Barbara Klughammer, Michel Ducreux

Annals of Oncology · 2014 · 44 citations · 12 references

Concepts

References

12